Ernexa Therapeutics Inc.

ERNA | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.96

+$0.13 (+3.39%)

At close: Sep 21, 2026, 4:00 PM ET

$3.85

-$0.11 (-2.78%)

Pre-market: Sep 22, 2026, 4:22 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.39%

(1D)

Rating

Updated: Aug 19, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.24M

1D Range

3.77 4.01

52W Range

3.18 71.50

Valuation (TTM)

PE -0.21

PB 0.39

EV/EBITDA 0.20

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target N/A

Cash Flow

FCF Yield -895.9%

SBC Adj. FCF Yield -998.0%

SBC Impact -11.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -37.4% | 37.5%

Dil EPS 3Y | 5Y 48.8% | 68.4%

FCF 3Y | 5Y 20.2% | 17.8%

Returns

ROA -194.1%

ROE -305.9%

ROIC -328.1%

Financial Health

Net Cash

$4.68M

Current Ratio 2.01

Interest Coverage -378.61

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs)....

Sector Healthcare

Industry Biotechnology

Employees 5

IPO Date Aug 28, 1991

Website www.ernexatx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.